The aim of this technology assessment, which has been commissioned by NICE through the NIHR Systematic Review Programme as part of the NICE Single Technology Appraisal process, is to review the submission received from the Aimmune Therapeutics on the clinical and cost-effectiveness evidence of Palforzia for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. The primary source of clinical effectiveness evidence submitted by Aimmune Therapeutics consists of two phase III RCTs (PALISADE and ARTEMIS) of Palforzia + avoidance versus placebo + avoidance and the follow-on study to the PALISADE trial (ARC004). The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from the company and the ERG’s critique, NICE will release appropriate clinical guidance. For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10713
Contacts
- Miriam Brazzelli; m.brazzelli@abdn.ac.uk